Phase I/Ib, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM54 Administered Intravenously to Patients With Selected Advanced Solid Tumors.
This study is testing a new experimental medication called PM54 in people with advanced solid tumors, such as bladder, kidney, or prostate cancer. Researchers are trying to find the safest dose of this drug and see how well it works when standard treatments have stopped being effective.
You may be eligible if you are 18 or older, can manage daily tasks on your own, and have a solid tumor that has progressed. Because this trial involves heart health, you cannot join if you have certain heart conditions or uncontrolled high blood pressure.
You will receive the medication through an IV drip. The doctors will closely monitor you to check for side effects and see how your cancer responds to the treatment as the dose is adjusted.
The study is currently recruiting patients at locations in San Antonio, Texas, as well as in Anderlecht, Belgium, and Madrid, Spain.
- 1This is an early-stage study testing the safety and effectiveness of a new drug.
- 2Participants must have advanced solid tumors that have not responded to standard therapy.
- 3Your heart health will be screened carefully before and during the study to ensure your safety.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.